Literature DB >> 2803913

Cinnarizine and flunarizine improve the tumour radiosensitisation induced by erythrocyte transfusion in anaemic mice.

P J Wood1, D G Hirst.   

Abstract

The ability of the calcium antagonists, cinnarizine and flunarizine, to enhance the radiosensitisation produced by the administration of an erythrocyte transfusion to anaemic, RIF-1 or SCCVII/St tumour bearing mice was determined. Erythrocyte transfusion alone increased radiation cell killing 10-fold in the RIF-1 tumour when given 0-4 h before X-rays. In contrast, the SCCVII/St showed only a 4-fold increase in sensitivity, apparent when erythrocytes were given 2-6 h before irradiation. The administration of 50 mg kg-1 cinnarizine or flunarizine to anaemic mice followed by erythrocyte transfusion 0 h before X-rays produced the same level of cell survival for both tumours, a 20-fold increase in cell killing for cinnarizine, and a 30-40-fold effect for flunarizine, even though at this time interval, the erythrocyte transfusion alone did not sensitise the SCCVII/St tumour to X-rays. Further investigations indicated, however, that the erythrocyte transfusion was necessary to achieve the sensitisation with the calcium antagonists, since giving flunarizine to anaemic mice alone only achieved a 4-fold increase in radiation cell killing. In addition, flunarizine given with erythrocyte transfusion 4 h before X-rays, in SCCVII/St, the optimal time for radiosensitisation in this tumour, did not further increase the level of cell killing achieved by flunarizine plus erythrocyte transfusion 0 h before X-rays.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803913      PMCID: PMC2247332          DOI: 10.1038/bjc.1989.215

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  The rheological effects of cinnarizine and flunarizine in normal and pathologic conditions.

Authors:  J De Cree; W De Cock; H Geukens; F De Clerck; M Beerens; H Verhaegen
Journal:  Angiology       Date:  1979-08       Impact factor: 3.619

2.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation.

Authors:  J M Brown
Journal:  Br J Radiol       Date:  1979-08       Impact factor: 3.039

3.  A new mouse tumor model system (RIF-1) for comparison of end-point studies.

Authors:  P R Twentyman; J M Brown; J W Gray; A J Franko; M A Scoles; R F Kallman
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

4.  Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats.

Authors:  W G Kaelin; S Shrivastav; D G Shand; R L Jirtle
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

5.  Definitive evidence for hypoxic cells influencing cure in cancer therapy.

Authors:  R S Bush; R D Jenkin; W E Allt; F A Beale; H Bean; A J Dembo; J F Pringle
Journal:  Br J Cancer Suppl       Date:  1978-06

6.  The effect of alterations in haematocrit on tumour sensitivity to X-rays.

Authors:  D G Hirst; J L Hazlehurst; J M Brown
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1984-10

7.  Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival.

Authors:  J Overgaard; H S Hansen; K Jørgensen; M Hjelm Hansen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

8.  Acute hypoxia in tumors: implications for modifiers of radiation effects.

Authors:  D J Chaplin; R E Durand; P L Olive
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

9.  Cinnarizine and flunarizine as radiation sensitisers in two murine tumours.

Authors:  P J Wood; D G Hirst
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

10.  Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Authors:  D G Hirst; J M Brown; J L Hazlehurst
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

View more
  2 in total

1.  Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia.

Authors:  Lingling Shi; Rui Huang; Yongrong Lai
Journal:  BMC Med Genomics       Date:  2021-05-13       Impact factor: 3.063

2.  Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells.

Authors:  Jose A Sandoval; Alexey Tomilov; Sandipan Datta; Sonia Allen; Robert O'Donnell; Thomas Sears; Kevin Woolard; Dmytro Kovalskyy; James M Angelastro; Gino Cortopassi
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.